Assembly Biosciences' (ASMB) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB - Free Report) in a report published on Friday,Benzinga reports.

Separately, Jefferies Financial Group upgraded shares of Assembly Biosciences from a "hold" rating to a "buy" rating and upped their price objective for the stock from $2.00 to $35.00 in a report on Friday, September 20th.

Assembly Biosciences Stock Performance

Assembly Biosciences stock traded down $0.22 on Friday, hitting $15.16. 30,908 shares of the stock traded hands, compared to its average volume of 25,238. The business's fifty day simple moving average is $16.12 and its 200 day simple moving average is $15.59. Assembly Biosciences has a 1 year low of $9.12 and a 1 year high of $19.93.

Insider Transactions at Assembly Biosciences

In other Assembly Biosciences news, major shareholder Alexander Schornstein acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, October 8th. The shares were acquired at an average cost of $14.58 per share, with a total value of $145,800.00. Following the transaction, the insider now owns 703,113 shares of the company's stock, valued at $10,251,387.54. The trade was a 1.44 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 394 shares of company stock valued at $5,894. Insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. raised its holdings in shares of Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 3,442 shares during the last quarter. Acadian Asset Management LLC raised its stake in Assembly Biosciences by 131.0% during the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company's stock valued at $184,000 after buying an additional 7,690 shares during the last quarter. FMR LLC lifted its holdings in shares of Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company's stock valued at $240,000 after buying an additional 3,635 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company's stock worth $753,000 after buying an additional 15,451 shares during the last quarter. Finally, Armistice Capital LLC purchased a new position in shares of Assembly Biosciences in the 2nd quarter worth $6,421,000. Hedge funds and other institutional investors own 19.92% of the company's stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.